KPTI News
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire NEWTON, Mass., Sept. 1, 2026 NEWTON, Mass., Sept. 1, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq...
PR Newswire
Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis
Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis PR Newswire NEWTON, Mass...
PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI PR Newswire NEW YORK, Aug. 27, 2026 NEW YORK, Aug. 27, 2026...
PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI PR Newswire NEW YORK, Aug. 20, 2026 NEW YORK, Aug. 20, 2026...
PR Newswire
Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Beats Revenue Estimates
Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of -51.63% and +5.70%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission
Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission PR Newswire NEWTON, Mass., Aug. 13, 2026...
PR Newswire
Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -80.00% and +12.76%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Karyopharm to Report Second Quarter 2026 Financial Results on August 13, 2026
Karyopharm to Report Second Quarter 2026 Financial Results on August 13, 2026 Karyopharm to Report Second Quarter 2026 Financial Results on August 13, 2026 PR Newswire NEWTON, Mass., Aug. 10, 2026 -- Conference Call Scheduled for Thursday, August 13, 2026, at 8:00 a.m. ET --NEWTON, Mass., Aug. 10...
PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI PR Newswire NEW YORK, Aug. 6, 2026 NEW YORK, Aug. 6, 2026...
PR Newswire
Relay Therapeutics, Inc. (RLAY) Reports Q2 Loss, Lags Revenue Estimates
Relay Therapeutics (RLAY) delivered earnings and revenue surprises of 0.00% and -86.97%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks